Asset Breakdown
58.8 B
Assets Non Current
34.6 B
Goodwill
Tax Assets
27.2 B
Current Assets
| Total Assets | 85.96 Billion | |
| Current Assets | 27.18 Billion | |
| Assets Non Current | 58.77 Billion | |
| Goodwill | 34.61 Billion | |
| Tax Assets | 5.31 Billion |
Thinking to short Merck (NYSE:MRK) based on its current debt commitments?
 | By Raphi Shpitalnik | Macroaxis Story |
Merck Inc is scheduled to announce its earnings today. The next earnings report is expected on the 3rd of November 2020. Merck Invested Capital is increasing as compared to previous years. The last year's value of Invested Capital was reported at 45.23 Billion. The current Invested Capital Average is estimated to increase to about 56.5 B, while Earnings before Tax are projected to decrease to under 10.9 B. While some of us are becoming more enthusiastic about healthcare space, let's examine Merck Company in greater detail to make a better estimate of its debt utilization. We will concentrate on if it could be a much better year for Merck shareholders.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Michael Smolkin
The company has 28 B in debt with debt to equity (D/E) ratio of 1.06, which is OK given its current industry classification. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Merck has an asset utilization ratio of 47.24 percent. This signifies that the company is making $0.47 for each dollar of assets. An increasing asset utilization means that Merck Company is more efficient with each dollar of assets it utilizes for everyday operations. Merck financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Merck, including all of Merck's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Merck assets, the company is considered highly leveraged. Understanding the composition and structure of overall Merck debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.
Understanding Merck Total Liabilities
Merck Company liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Merck Company has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Merck balance sheet include debt obligations and money owed to different Merck vendors, workers, and loan providers. Below is the chart of Merck short long-term liabilities accounts currently reported on its balance sheet. You can use Merck Company financial leverage analysis tool to get a better grip on understanding its financial positionHow important is Merck's Liquidity
Merck financial leverage refers to using borrowed capital as a funding source to finance Merck Company ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Merck financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Merck's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Merck's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Merck's total debt and its cash.
A Deeper Perspective
The recent indifference towards the small price fluctuations of Merck Company may encourage traders to take a closer look at the firm as it closed today at a share price of 77.63 on 6,824,952 in trading volume. The company directors and management did not add any value to Merck Inc investors in July. However, most investors can still diversify their portfolios with Merck Company to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently 1.54. The below-average Stock volatility is a good sign for longer-term investment options and for buy-and-hold investors.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Merck Company. Please refer to our Terms of Use for any information regarding our disclosure principles.